KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Xichun Hu, Qingyuan Zhang, Leiping Wang, Jian Zhang, Quchang Ouyang, Xiaojia Wang, Wei Li, Weimin Xie, Zhongsheng Tong, Shusen Wang, Faliang Xu, Tao Sun, Wei Liu, Zhendong Chen, Jinsheng Wu, Ying Wang, Haixia Wang, Min Yan, Xinshuai Wang, Jingfen Wang, Feilin Cao, Yingying Du, Yongqiang Zhang, Lilin Chen, Ping Lu, Sanyuan Sun, Ruiwen Zhang, Aimin Zang, Xiuqing Nie, Yuan Lei

Signal Transduct Target Ther 10(1) 56

PMID39956849
PMCIDPMC11830773
DOI10.1038/s41392-025-02149-3
发表日期2025-02-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

This phase III trial aimed to compare ARX788, a site-specific, construct-homogeneous antibody-drug conjugate, with lapatinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) who had progressed on one line of trastuzumab based regimen. Eligible patients were randomized (1:1) to receive ARX788 (1.5 mg/kg, IV, Q3W) or lapatinib plus capecitabine (LC: lapatinib 1250 mg QD; capecitabine 1000 mg/m2 BID, days 1-14, Q3W) and stratified by prior chemotherapy lines (0-1 versus >1) and visceral metastasis (yes versus no). The primary outcome was progression-free survival (PFS) assessed by a blinded independent central review (BICR). A total of 441 patients were randomly assigned to receive either ARX788 (n = 221) or LC (n = 220). The median PFS was 11.3 (95% confidence interval [CI], 8.4-13.8) months with ARX788 compared with 8.2 (95% CI, 6.9-8.7) months with LC, as per BICR (hazard ratio [HR] 0.64, p = 0.0006). Frequencies of treatment-related adverse events (TRAEs) of any grade were 98.6% and 99.1% for ARX788 and LC, respectively. Grade ≥3 TRAEs were 41.4% and 40.0%, respectively, the most common adverse events were blurred vision (12.3%), dry eye (9.1%), keratopathy (5.9%), and interstitial lung disease (ILD, 5.9%) with ARX788; hand-foot syndrome (18.1%) and hypokalemia (5.1%) with LC; all the hematological and gastrointestinal events of grade ≥3 with ARX788 were less than 3%. Six treatment-related deaths occurred, with three cases possibly related to ILD. ARX788 significantly improved PFS compared with LC in patients with HER2-positive ABC with a distinct toxicity profile, supporting it as a potential treatment option.

KM 提取结果

2 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure2 个面板

Fig. 2

Fig. 2 Kaplan–Meier curves for PFS. a PFS assessed by BICR. b PFS assessed by INV. PFS progression-free survival, BICR blinded independent central review, INV investigators, LC lapatinib plus capecitabine

A

Progression-free Survival

Fig. 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:extreme upward reversal曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
B

Progression-free Survival

Fig. 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 4

Fig. 4 Kaplan–Meier curves for OS. OS overall survival, LC lapatinib plus capecitabine

Kaplan_Meier_curves_for_OS

OS

Fig. 4 · Panel Kaplan_Meier_curves_for_OS

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Kaplan_Meier_curves_for_OS 是同一 Fig. 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Trial profile
非 KM Figure
Fig. 3Fig. 3 PFS assessed by BICR in key subgroups. PFS progression-free survival, LC lapatinib plus capecitabine
非 KM Figure
Fig. 5Fig. 5 OS in key subgroups. OS overall survival, LC lapatinib plus capecitabine
非 KM Figure